Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Up 134.0% in January

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 12,400 shares, a growth of 134.0% from the December 31st total of 5,300 shares. Based on an average daily volume of 49,800 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their target price on shares of Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, January 13th.

Barinthus Biotherapeutics Stock Up 0.5 %

Shares of Barinthus Biotherapeutics stock traded up $0.01 during trading on Friday, reaching $1.01. The company’s stock had a trading volume of 13,858 shares, compared to its average volume of 41,033. The business has a 50 day moving average price of $1.03 and a 200-day moving average price of $1.21. The company has a market capitalization of $40.43 million, a P/E ratio of -0.67 and a beta of -0.81. Barinthus Biotherapeutics has a 12-month low of $0.80 and a 12-month high of $4.16.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.23. The company had revenue of $14.97 million for the quarter. During the same quarter in the previous year, the business posted ($0.37) earnings per share. Research analysts predict that Barinthus Biotherapeutics will post -1.38 EPS for the current fiscal year.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.